Hepatitis B (chronic hepatitis B) patients refer to those who are positive in hepatitis B virus detection and whose course of disease exceeds half year, or whose onset date is not clear, with the clinical manifestation of chronic hepatitis. According to data of Global Data, size of the hepatitis B drug market will reach RMB 20 billion in China by 2020, and RMB 30 billion in the longer term; the hepatitis B drug market demand is still huge, and will continue to maintain high growth in the future.
At present, the relevant chemical drugs in China are mainly divided into interferons and oral nucleoside drugs. The common nucleoside drugs in China mainly include lamivudine, adefovir dipivoxil, entecavir, tenofovir disoproxil fumarate (TDF), and telbivudine, etc.
Chia Tai Tianqing can be said to be the top leader in the liver health field of China, with four products marketed at present: Entecavir Dispersible Tablets (Runzhong), Adefovir Dipivoxil Capsules (Mingzheng), Entecavir Maleate Tablets (Tianding), and Tenofovir Disoproxil Fumarate Tablets (Qingzhong), and the market sales of Runzhong exceeding RMB 3 billion in 2017. The company is now developing the new-generation antiviral drug TAF (tenofovir alafenamide), and bringing many Class 1.1 innovative drugs in the liver disease area successively into clinical studies. The TLR7 agonist developed by it mainly has the antiviral function against HBV and HIV, etc., and is similar to Gilead’s GS-9620 in terms of the molecular structure, with its international development right licensed to J & J.
Among the relevant pharmaceutical products accepted by CDE, products of Chengdu Brilliant and Chia Tai Tianqing have been first in passing the approval, followed by products of Qilu Pharmaceutical. The market will face huge competition and the previous market pattern may be overturned as the generic drugs enter the market. Predictably, TDF will occupy market shares of other pharmaceutical products in the near future; the future competition of the hepatitis B drug market will be mainly between TDF and entecavir, and the previous market pattern between original drugs and generic drugs will undergo dramatic changes in the near future.
As TDF will occupy market shares of other pharmaceutical products in the near future, here, take TDF for instance. According to the data of Yaozh.com, there are about 188 TDF pharmaceutical products that have been marketed, issued approvals, filed ANDAs, or under review in China, showing the fierce competition.
Also called the "second generation of TDF", TAF (trade name: Vemlidy) is another anti-HBV blockbuster drug launched by Gilead following TDF, and was approved on November 10, 2016.
Read More
(All Rights Reserved)